Press release
Siemens Healthineers Signs Agreement with A1 Life Sciences to Support Global Efforts to Track Variants
Published on September 9, 2021
Download this press release(pdf, 184.00 KB)
Contact
1
CE-IVD labelled for diagnostic use in the EU. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
A1 Life Sciences
A1 Life Sciences, founded in 2019, is a pioneering biotechnology company providing smart and reliable IVD & Research tools, products and complete lab solutions, ranging from academic research to routine healthcare applications across a wide range of portfolios and with references from thousands of professionals. In addition to being the manufacturer of 16 different COVID-19 products, A1 Life Sciences provides R&D facilities for research projects, cleanroom production facilities for finished products, and a worldwide marketing network for ready-to-sell products. A1 Life Sciences builds creative local partnerships for supplying reliable and affordable COVID-19 solutions to both MOHs and private sectors. For more information, visit http://www.a1lifesciences.com.tr/